| Market Capitalization (Millions $) |
10,775 |
| Shares
Outstanding (Millions) |
52 |
| Employees |
925 |
| Revenues (TTM) (Millions $) |
777 |
| Net Income (TTM) (Millions $) |
-192 |
| Cash Flow (TTM) (Millions $) |
2 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for Central Nervous System (CNS) disorders, including depression, chronic pain, and other neurological conditions. Established in 2012, Axsome has its headquarters in New York, United States.
The company utilizes its proprietary technology and expertise to create novel treatment approaches that offer a new option for patients suffering from CNS disorders. Axsome's core competencies include drug discovery, preclinical and clinical development, and regulatory affairs. The company leverages its strengths and partnerships in these areas to accelerate the development of its therapeutic candidates.
Axsome's portfolio includes several product candidates that are either in the development or clinical testing stage. Some notable candidates include AXS-05, AXS-07, and AXS-1 AXS-05 is a combination of dextromethorphan and an inhibitor of the monoamine oxidase enzyme. This drug is being evaluated for the treatment of major depressive disorder and treatment-resistant depression. AXS-07 is a combination of an anti-inflammatory drug and a triptan, being developed for the treatment of migraines. AXS-12, on the other hand, is being developed for the treatment of narcolepsy.
Axsome has also been actively engaged in several partnership and licensing agreements to advance its pipeline of products. In 2018, the company signed a global license agreement for AXS-05 with Pfizer, which granted them rights to develop and commercialize this product in markets outside the United States. More recently, in 2021, Axsome signed a licensing agreement with Bausch Health that will allow the latter to manufacture and commercialize AXS-07 for migraines in Canada.
The company has been rapidly growing in the past few years, with its share price increasing considerably in response to positive clinical data and regulatory approvals. Axsome has also received several awards and recognitions for its innovative work, including being named as one of the top biotech companies to work for in 2021 by BioSpace.
In conclusion, Axsome Therapeutics Inc is a leading biopharmaceutical company that focuses on the development of innovative therapies for CNS disorders. The company has an extensive portfolio of product candidates, with several in various stages of development and clinical testing. Axsome has been recognized for its innovative work in the field of CNS disorders and has also been actively engaged in strategic partnerships to boost its progress. As the company's pipeline progresses, it has the potential to make a significant impact on the treatment of CNS disorders, particularly in areas where current treatment options are inadequate.
Company Address: One World Trade Center New York 10007 NY
Company Phone Number: 332-3241 Stock Exchange / Ticker: NASDAQ AXSM
|
2.3% 
185.81 %